The Pharmaceutical Market: Ireland

Publisher Name :
Date: 25-Apr-2013
No. of pages:

THE PHARMACEUTICAL MARKET: IRELAND – REVIEW

Ireland has experienced rapid economic growth over the past 20 years, and has invested in large scale renovation and redevelopment of its healthcare infrastructure. That said, the country is in the midst of a severe economic downturn, with GDP expected to contract in 2012. Due to the recession and Ireland’s huge budget deficit, the country has received an 85 billion euro (US$113 billion) bailout from the EU and IMF. As a result, the government faces an extremely tight financial operating environment in the next few years. It has generally sought to protect healthcare, especially frontline services, from the kinds of cuts experienced elsewhere, but health is not unaffected. A progression of measures has been introduced as the economic position has worsened, most recently the Budget 2011 and related National Recovery Plan.

In March 2011, the government announced plans to introduce Universal Health Insurance (UHI) by 2016. Underpinning the UHI system will be the principle of access according to need and payment according to ability to pay. Insurance with a public or private insurer will be compulsory, with insurance payments related to ability to pay. The government is also planning to remove fees for GP care, which will be implemented in phases, firstly for claimants of free drugs under the Long-Term Illness scheme and the High-Tech Drugs scheme, before being extended to all. Under UHI, public hospitals will no longer be managed by the HSE. They will be independent, not-for-profit trusts with managers accountable to their boards. Hospitals will be paid according to the care they deliver and will be incentivised to deliver more care in a ‘money follows the patient’ system. The government has also reiterated plans to introduce reference pricing and generic substitution, as cost saving measures.

Most global companies have some manufacturing presence in the pharmaceutical market in Ireland. Drugs are either produced in finished form for export, or exported on to other facilities for finishing. A number of branded drugs go off patent in 2012, including Pfizer’s Lipitor and Eli Lilly’s Zyprexa, which could have a negative impact on the industry. However, several multinational companies have been moving into the biologic sector in preparation for the loss of profit from these blockbuster drugs. While the multinational presence is very strong, Ireland has very few domestic producers. In September 2011, Alkermes completed its merger with Elan Drug Technologies (EDT) to form a new company, Alkermes Plc., which is headquartered in Dublin. In September 2011, Pfizer announced it was to invest US$200.0 million at its Grange Castle site, to add two processing suites and to expand current production and product testing capabilities. In September 2011, MSD opened its new R&D centre at its Ballydine site, creating 70 new jobs. Previously, in June 2011, MSD opened two new facilities at the site in Brinny.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

The Pharmaceutical Market: Ireland

Table Of Contents
N/A

  • Overview of the Global Retail Market
    The global retail industry continued to grow despite the difficult economic conditions in the world. In the fiscal year of 2011, sales-weighted, currency-adjusted revenue rose by 5.1% to $4.271 trillion for the world’s top 250 retailers. According to GRDI (Global Retail Development Index), in 2013 Brazil occupied the top spot in retail development. Chile and [...]
  • Bright Future Predicted for the Tourism Industry in Singapore
    Travel and tourism industry in Singapore has been growing at a steady rate and is considered to be a major contributor to the economic growth of the country. In 2012, Singapore’s IVA (International Visitors Arrivals) reached a record high of 14.5 million, with a growth rate of 10.1% year-on-year. In recent years, inbound travel to [...]
  • Potential of Staffing Market in United States
    The staffing industry places individuals into contract, temporary and permanent positions in firms around the world. Major staffing markets include France, Spain, Italy and Japan as well as many emerging markets. Temporary staffing around the world has been growing, but in US temporary market has been flat since 2006. The majority of staffing revenue majorly [...]
  • Growth in the Indian Watch Industry
    Earlier, in India watches were seen as a luxury item. However, watches are now witnessing a fundamental change in perception, and are now gaining respect as an essential utility item. With the liberalization of the Indian market, coupled with the rising purchasing power of the young and consumerist Indians, watch industry in India seems to [...]
  • Global Retail Ready Packaging Market to Witness Steady Growth
    The market for retail ready packaging has witnessed impressive growth in recent years with boom in the retail industry. Retail ready packaging, also known as shelf-ready packaging is designed for the retail outlet, ready to be placed on shelf without any need for unpacking or repacking. In 2011, the global market for retail packaging was [...]
  • Cambodia and Laos Pharmaceuticals and Healthcare Report Q2 2014
    Published: 16-Apr-2014        Price: US $1295 Onwards        Pages: 65
    BMI View: Low health and pharmaceutical expenditures will continue to limit the attractiveness of the pharmaceutical market in Cambodia. Given such a profile, the country will present more commercial benefits to companies dealing with inexpensive generic drugs and over-the-counter products than innovative pharmaceuticals. Headline Expenditure Projections ? Pharmaceuticals: KHR828.7bn (US$210mn) in 2013 to KHR921.9bn (US$230mn) in 2014; +11.2% in local currency terms and +11.8% in US dollar terms......
  • Czech Republic Pharmaceuticals and Healthcare Report Q2 2014
    Published: 16-Apr-2014        Price: US $1295 Onwards        Pages: 104
    BMI View: Overall, the Czech healthcare system is facing severe challenges as it struggles to contain budget deficits. At the same time, demand for the latest pharmaceuticals and access to healthcare services is expected to continue its steady growth trajectory, putting pressure on the state and insurers to raise premiums or redistribute funding. Following the release of pharmaceutical sales data by the SUKL, we have significantly revised down historical values for 2013 and forecasts from 2014 o......
  • Denmark Pharmaceuticals and Healthcare Report Q2 2014
    Published: 16-Apr-2014        Price: US $1295 Onwards        Pages: 60
    BMI View: Although Denmark's pharmaceutical market is relatively small compared to other Western European countries, the demand for high quality healthcare will remain elevated by an increasing and ageing population. This demand could provide opportunities for private healthcare providers to expand as the government continues its restructuring and cost containment measures across the public healthcare sector. Headline Expenditure Projections ? Pharmaceuticals: DKK20.20bn (US$3.58bn) in 2013 to D......
  • Iraq Pharmaceuticals and Healthcare Report Q2 2014
    Published: 16-Apr-2014        Price: US $1295 Onwards        Pages: 75
    BMI View: The projected growth of Iraq's pharmaceutical market in 2014 and 2015 is linked to an oildriven economic expansion, which is dependent on the government's ability to represent and appease the country's factions. Given the government's expansionary fiscal policy, spending on education, health and public services will be elevated over the coming quarters. In particular, Baghdad will seek to modernise healthcare provision, in a view to improve support to its rule. Nevertheless, there are ......
  • Lithuania Pharmaceuticals and Healthcare Report Q2 2014
    Published: 16-Apr-2014        Price: US $1295 Onwards        Pages: 98
    BMI View: We expect the Lithuanian pharmaceutical market to post a five-year compound annual growth rate (CAGR) of 4.4%, rising to a value of LTL2.16bn (US$751mn) in 2018. While double-digit annual growth rates are firmly in the past, some opportunities continue to exist in light of epidemiological factors and an ageing population. The upcoming switch to the euro promises to boost purchasing power and stabilise the pharmaceutical market. However, the Lithuanian market will continue to represent ......
  • Sri Lanka Pharmaceuticals and Healthcare Report Q2 2014
    Published: 16-Apr-2014        Price: US $1295 Onwards        Pages: 78
    BMI View: A better-than-expected outlook for Sri Lanka's economy has led us to upwardly revise our pharmaceutical and healthcare forecasts. The government has introduced price controls on wholesale and retail prices of imported drugs, which will limit trade. However, the government's focus on imports of lowcost drugs directly from the governments of Bangladesh and Thailand, using the state pharmaceutical corporation, will limit dependency on Indian exporters. Furthermore, the government's streng......
  • Venezuela Pharmaceuticals and Healthcare Report Q2 2014
    Published: 16-Apr-2014        Price: US $1295 Onwards        Pages: 126
    BMI View: Foreign currency controls and drug price cuts will continue to affect pharmaceutical companies' profitability, with the currency devaluation and high inflation exacerbating the situation. A close relationship and effective communication with the Venezuelan government are vital for the survival of domestic pharmaceutical companies. As the Venezuelan government tries to increase access to medicines, more co-ordination with drug producers to address these issues will become necessary. Hea......
  • Saudi Arabia Pharmaceuticals and Healthcare Report Q2 2014
    Published: 9-Apr-2014        Price: US $1295 Onwards        Pages: 119
    BMI View: We hold a very positive outlook towards growth in the Saudi Arabian medicines market over the next decade, with pharmaceutical demand underpinned by a number of factors. However, risks to our outlook are to the downside, some of which include greater-than-expected drops in the oil price, the government's failure to deliver on healthcare infrastructure expansion and medicine price cuts in the short term. Headline Expenditure Projections ? Pharmaceuticals: SAR22.7bn (US$6.06bn) in 2013 t......
  • Serbia Pharmaceuticals and Healthcare Report Q2 2014
    Published: 9-Apr-2014        Price: US $1295 Onwards        Pages: 123
    BMI View: While per capita expenditure on drugs is increasing steadily, Serbia's overall pharmaceutical market is still underdeveloped. Serbia frequently faces medicine shortages, as some retailers and pharmacists are unable to earn profits from the sale of these medicines, which is impacting patients. As the country continues its economic convergence with developed Europe, drug consumption is expected to rise. Meanwhile, financial inefficiencies within the health insurance system compel the Nat......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs